Investment Analysts’ Weekly Ratings Changes for Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (NYSE: TMO) has recently received a number of price target changes and ratings updates:

  • 10/26/2018 – Thermo Fisher Scientific was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $247.00 price target on the stock. According to Zacks, “Thermo Fisher ended the third quarter on a promising note with both earnings and revenues surpassing the consensus mark. The company saw strength in all end markets categorized by customer type or geography. It particularly registered solid international performance with strong growth in Asia-Pacific including China. Also, a series of product launches with progress in precision medicine initiatives aided its performance. The company’s recently-closed acquisition of Advanced Bioprocessing business from BD should add complementary cell culture products to Thermo Fisher’s bioproduction offerings. Also, the company’s initiative to buy Gatan to boost electron microscopy suite buoys optimism. On the flip side, Thermo Fisher’s business segments are getting impacted by unfavorable business mix. Also, competitive headwinds and escalating costs pose a threat. Thermo Fisher outperformed its industry in the past three months.”
  • 10/25/2018 – Thermo Fisher Scientific had its price target raised by analysts at Morgan Stanley from $254.00 to $260.00. They now have an “overweight” rating on the stock.
  • 10/25/2018 – Thermo Fisher Scientific had its price target raised by analysts at Robert W. Baird from $256.00 to $264.00. They now have an “outperform” rating on the stock.
  • 10/18/2018 – Thermo Fisher Scientific was downgraded by analysts at Cleveland Research from a “buy” rating to a “neutral” rating.
  • 10/10/2018 – Thermo Fisher Scientific had its price target raised by analysts at Morgan Stanley from $242.00 to $254.00. They now have an “overweight” rating on the stock.
  • 10/10/2018 – Thermo Fisher Scientific had its price target raised by analysts at Citigroup Inc from $260.00 to $280.00. They now have a “buy” rating on the stock.
  • 10/9/2018 – Thermo Fisher Scientific is now covered by analysts at UBS Group AG. They set a “buy” rating and a $295.00 price target on the stock.
  • 10/1/2018 – Thermo Fisher Scientific was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $274.00 price target on the stock. According to Zacks, “Thermo Fisher has outperformed its industry in the past three months. We are encouraged by the company’s solid international performance on strong growth in China in the last reorted quarter. Thermo Fisher also saw strength in all end markets categorized either by customer type or geography. Also, a series of product launches along with major progress in precision medicine initiatives aided the company’s performance. Moreover, the Patheon buyout has been substantially adding an impetus to the company’s value proposition for biopharma customers. Also, Thermo Fisher’s initiative to buy Gatan in order to boost electron microscopy suite buoys optimism. On the flip side, in the reported quarter, Thermo Fisher’s business segments were impacted by unfavorable business mix. Also, competitive headwinds and rising operating costs continue to pose a threat.”
  • 9/24/2018 – Thermo Fisher Scientific had its price target raised by analysts at Barclays PLC from $250.00 to $275.00. They now have an “overweight” rating on the stock.
  • 9/17/2018 – Thermo Fisher Scientific was downgraded by analysts at Goldman Sachs Group Inc from a “buy” rating to a “neutral” rating.

TMO opened at $238.23 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.27 and a current ratio of 1.84. Thermo Fisher Scientific Inc. has a 1-year low of $181.51 and a 1-year high of $249.95. The company has a market capitalization of $94.34 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 1.70 and a beta of 1.08.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.55 by $0.07. The firm had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.70 billion. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.31 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 11.04 EPS for the current fiscal year.

In other news, CEO Marc N. Casper sold 125,520 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $247.50, for a total transaction of $31,066,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.49% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its position in shares of Thermo Fisher Scientific by 0.7% during the 3rd quarter. Wells Fargo & Company MN now owns 3,213,226 shares of the medical research company’s stock valued at $784,285,000 after buying an additional 23,811 shares during the period. Dimensional Fund Advisors LP increased its holdings in Thermo Fisher Scientific by 3.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,670,961 shares of the medical research company’s stock valued at $553,246,000 after purchasing an additional 82,255 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Thermo Fisher Scientific by 1.7% in the 2nd quarter. Janus Henderson Group PLC now owns 2,036,659 shares of the medical research company’s stock valued at $421,880,000 after purchasing an additional 34,401 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Thermo Fisher Scientific by 3.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,566,563 shares of the medical research company’s stock valued at $324,498,000 after purchasing an additional 46,519 shares during the last quarter. Finally, Findlay Park Partners LLP increased its holdings in Thermo Fisher Scientific by 8.9% in the 2nd quarter. Findlay Park Partners LLP now owns 1,525,000 shares of the medical research company’s stock valued at $315,889,000 after purchasing an additional 125,000 shares during the last quarter. 85.22% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: Initial Public Offering (IPO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply